Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- , ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

As recently as last month, the biotech had been setting out plans for a phase 3 trial of the combo treatment for later in ...

NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...

Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief ...